Earlier in October 2006, Biotica has licensed all rights of rapamycin analogue program to Wyeth Pharmaceuticals, which was acquired by Pfizer in October 2009.
Biotica CEO Edward Hodgkin said their compounds are supported by a data package generated by Pfizer, and show evidence of meaningful differentiation in diseases with significant unmet need.
Pfizer Immunology and Autoimmunity Research Unit chief scientific officer Mary Collins said the decision to return this program to Biotica was made as part of Pfizer’s portfolio review process.